GENinCode tests provide patients and physicians with globally leading risk assessment tools to inform cardiovascular preventive care and treatment. Our technologies combine monogenic, polygenic and clinical information to provide advanced patient risk assessment to predict and prevent cardiovascular disease.
GENinCode provides genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Harnessing the power of both monogenic and polygenic risk assessment to combat the world’s most prevalent health problem.
GENinCode technology offers physicians globally leading risk assessment tools. Our tests combine clinical algorithms and artificial intelligence (AI) to provide advanced patient risk assessment to predict cardiovascular disease and enable prevention.
With over 15 years research and development in cardiovascular genomics, and in collaboration with leading institutions and clinical key opinion leaders, GENinCode has amassed a deep knowledge and understanding of the interactions between a patient’s genomic profile, lifestyle, and clinical risk factors.
GENinCode is a predictive genetics company that specializes in regulatory approved clinical genetic tests for the risk assessment and prevention of heart disease and ovarian cancer. Our team, culture and mission are focused on revolutionizing preventative medicine by delivering personalized genetic diagnosis and polygenic risk assessment to provide tailored preventive treatment.
Our clinical tests have been developed and validated on large multi-ancestry population datasets and published extensively in leading clinical journals. We use our digital proprietary software system ‘SITAB’ to combine a patient’s genetic profile with clinical risk factors to predict and prevent heart disease and for the surveillance of ovarian cancer.
As a Company we specialise in Polygenic risk scores (PRS) to estimate an individual’s genetic likelihood of developing disease by aggregating the effects of many genetic variations to detect the risk of disease earlier so that treatment can be targeted at prevention.
GENinCode UK Limited
Oxford Science Park,
John Eccles House
Robert Robinson Avenue
Oxford, OX4 4GP
GENinCode S.L.U.
Rambla Egara, 235,
ES- 08224
Terrassa-Barcelona
GEN inCode U.S. Inc.
5 Mason, Suite 200
Irvine, CA 92618
